Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia
- 5 July 2025
- journal article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (5) , 1-17
Abstract
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.Keywords
Funding Information
- the Izmir University of Economics (2023-05)
This publication has 68 references indexed in Scilit:
- Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunitiesAnnals of Hematology, 2024
- Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)Current Oncology Reports, 2024
- Bioactivities and the structural modification of Parthenolide: a reviewMedicinal Chemistry Research, 2023
- Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cellsNatural Products and Bioprospecting, 2023
- Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled TrialsClinical Lymphoma Myeloma and Leukemia, 2021
- Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125Annals of Hematology, 2020
- Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose AdjustmentsClinical Therapeutics, 2017
- Parthenolide: from plant shoots to cancer rootsDrug Discovery Today, 2013
- Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2Tumor Biology, 2012
- Wortmannin induced apoptosis of leukemia cells by reducing PI3K/AktThe Chinese-German Journal of Clinical Oncology, 2010